{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:50:18Z","timestamp":1785887418661,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtha.2026.04.036","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:07:50Z","timestamp":1778760470000},"page":"2946-2956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and outcomes of antiphospholipid syndrome after unprovoked venous thromboembolism: a multicenter real-world data analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-5927","authenticated-orcid":false,"given":"Abhinav","family":"Mathur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3066-176X","authenticated-orcid":false,"given":"Catrin","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5844-6158","authenticated-orcid":false,"given":"Shabnam","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3871-8491","authenticated-orcid":false,"given":"Lara","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-128X","authenticated-orcid":false,"given":"Karen A.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3298-9431","authenticated-orcid":false,"given":"Claire","family":"Lentaigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8762-1149","authenticated-orcid":false,"given":"Raza","family":"Alikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-0486","authenticated-orcid":false,"given":"Andrew J.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-3678","authenticated-orcid":false,"given":"Mohammed M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.04.036_bib1","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1111\/j.1538-7836.2010.03991.x","article-title":"Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: Recommendation for acceptable rates and standardized reporting","volume":"8","author":"Kearon","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib2","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1182\/bloodadvances.2020002268","article-title":"Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?","volume":"4","author":"\u00c1inle","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.036_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.18239","article-title":"Thrombophilia testing: a British Society for Haematology guideline","volume":"198","author":"Arachchillage","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.036_bib5","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.036_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/sj.thj.6200206","article-title":"Antiphospholipid antibodies and thrombosis: strength of association","volume":"4","author":"Galli","year":"2003","journal-title":"Hematol J"},{"key":"10.1016\/j.jtha.2026.04.036_bib7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjh.19635","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"205","author":"Arachchillage","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.036_bib8","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.036_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.04.036_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.04.036_bib12","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jtha.2026.04.036_bib14","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jtha.2026.04.036_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/jth.14720","article-title":"Prevalence of confirmed antiphospholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism","volume":"18","author":"Miranda","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib18","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1016\/j.jtha.2025.07.039","article-title":"Being stung by the taipan\u2014high rates of false positivity for lupus anticoagulant using taipan snake venom time in patients on warfarin with a low probability of antiphospholipid syndrome","volume":"23","author":"Platton","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0038-1650551","article-title":"Deep venous thrombosis and lupus anticoagulant","volume":"76","author":"Simioni","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1191\/096120398678919688","article-title":"Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis","volume":"7","author":"Wahl","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.jtha.2026.04.036_bib22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol (Hoboken)"},{"key":"10.1016\/j.jtha.2026.04.036_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102856","article-title":"Efficacy and safety of direct oral anticoagulants compared with warfarin in antiphospholipid syndrome. Results of a multicenter retrospective cohort study","volume":"9","author":"Elsebaie","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2024.03.013","article-title":"Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation","volume":"237","author":"Bakow","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.036_bib25","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/jth.15518","article-title":"Single or triple positivity for antiphospholipid antibodies in \u201ccarriers\u201d or symptomatic patients: untangling the knot","volume":"19","author":"Bertin","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.036_bib26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.17634","article-title":"Direct oral anticoagulant use in patients with antiphospholipid syndrome and unprovoked venous thromboembolism: a single centre experience","volume":"195","author":"Doyle","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:21:14Z","timestamp":1785885674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1538783626002886"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.036","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and outcomes of antiphospholipid syndrome after unprovoked venous thromboembolism: a multicenter real-world data analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}